恒指跌幅扩至近500点失守26,700 两大医药及手机股挫逾4%-7%
美股昨晚先升後回，联储局如期维持利率不变，但声明指消费支出放缓至仅温和，主席鲍威尔更指中国「武肺」疫情对经济前景构成不确定性，美企季绩参差，加上美国12月NAR季调後成屋销售环比意外急降4.9%，道指及纳指仅续微，标普反覆微吐0.1%。
内地新型冠状病毒感染肺炎确诊个案突破7,700宗，死亡人数增至170人。亚太区股市今早普遍受压，尤其是台湾加权指数鼠年首个交易日复市追泻592点或4.9%，报11,526。
港股承鼠年首个交易日追挫789点或2.8%颓势，今早低开130点失守百天线後，跌幅持续扩大至491或1.8%，报26,669，为去年12月11日以来最低，成交额394亿元。
蓝筹股除太古A(00019.HK)逆市微弹外，无一幸免。瑞信指「武肺」疫情将影响内地智能手机生产及销售，瑞声(02018.HK)及舜宇(02382.HK)低见55.3元及128.6元，现造55.45元及129.2元，续挫7.4%及6.7%，後者失守50天线(135.4元)。此外，重磅股腾讯(00700.HK)及中移动(00941.HK)跌1.3%及3.8%，分别报378.4及65元，後者失守10天及20天线。
石药(01093.HK)及中生制药(01177.HK)连跌第四天，股价均失守百天线(17.98元及10.97元)，低见17.68元及10.6元，分别报17.72元及10.64元，续挫4.1%及4.5%。
内地肺炎疫情肆虐，银娱(00027.HK)、金沙(01928.HK)及蒙牛(02319.HK)续跌2.4%-2.9%，分别报51.9元/37.85元/30.25元，前两者股价跌破牛熊线。
金融股以友邦(01299.HK)、中国平安(02318.HK)、中银(02388.HK)及国寿(02628.HK)沽压较大，股价依次续跌1.5%-2.8%，分别报79.6元/90.25元/19.3元，後者创逾三个月低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
